Modulight Biotherapeutics received an undisclosed investment to advance its portfolio of optogenetics-based therapies, which includes innovations aimed at treating rare neurological disorders.
Modulight Biotherapeutics received an undisclosed investment to advance its portfolio of optogenetics-based therapies, which includes innovations aimed at treating rare neurological disorders.
